Le Lézard
Classified in: Health
Subjects: PER, MAT

Katie Mapel Takes the Helm as Director of Marketing for My Life's Simple/ReAction

MOORESVILLE, N.C., Nov. 19, 2019 /PRNewswire-PRWeb/ -- We are pleased and excited to officially welcome Katie Mapel to the My Lifes Simple/ReAction family as our new Director of Marketing. While there are several identified long term projects, objectives and strategies Katie will be working on, her initial focus and top priority will be the creation and implementation of a number of exciting, new Ambassador tools to help you build and grow your businesses.

She has extensive experience in the direct selling space, having spent 20 years with one of the largest and most successful direct selling companies in the world ? a company she helped grow from a six-year old company operating only in the U.S. to an established global brand in 26 countries across 5 continents. During her tenure, she championed for the distributor channel, designing and delivering countless award-winning programs and tools. Katie understands the unique challenges and opportunities of direct selling and the mindset of our Ambassadors, so we have no doubt you will see and feel the impact of her experience and expertise in your businesses very soon.

Katie had this to say about joining our team: "I grew up in direct selling, having spent my entire professional career in this industry. There is no other industry in the world like it, and no other industry I would rather commit my time and talents to. And there is no other company quite like yours. Your products, compensation plan and leadership are second to none. My Lifes Simple and ReAction are on track to transform both the direct selling and CBD industries, and I can't wait to be a part of it."


SOURCE My Life's Simple

These press releases may also interest you

9 déc 2019
CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II...

9 déc 2019
Following the release of details from a surprise billing agreement between Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) and House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ) and...

9 déc 2019
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 11,115,165...

9 déc 2019
A team led by Stavros Zanos, MD, PhD, assistant professor at the Feinstein Institutes for Medical Research, has published an overview of how bioelectronic medicine may be used to treat pulmonary arterial hypertension (PAH) in the Springer Nature...

9 déc 2019
North Bud Farms Inc. ("NORTHBUD" or the "Company") is pleased to announce the appointments of Mr. Ryan Brown as Executive Chairman of the Board of Directors, Mrs. Jennifer Ross-Carriere to the Board of Directors and Mr. Sean Homuth as Chief...

9 déc 2019
UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune...

News published on 19 november 2019 at 10:00 and distributed by: